Chimiothérapie intra-artérielle en Israël — recevez 3 correspondances personnalisées de cliniques

Intra-arterial chemotherapy (IAC) is a targeted cancer treatment that delivers concentrated medication directly into the artery supplying a tumor. By using a microcatheter to bypass systemic circulation, physicians maximize drug potency at the disease site while significantly reducing toxicity and side effects throughout the body.

• Targeted delivery: Catheters guide medication from the femoral artery to specific tumor-feeding vessels.
• Retinoblastoma treatment: Primary method for pediatric eye cancer, achieving over 90% eye salvage rates.
• Reduced toxicity: Minimizes systemic side effects like weight loss, anemia, and high infection risks.
• Specialized agents: Common drugs include Melphalan, Topotecan, and Carboplatin for localized tumor destruction.

Bookimed Expert Insight: Israeli centers like Sourasky and Sheba specialize in globe-sparing techniques for advanced retinoblastoma. Data shows centers performing 34,000+ annual operations often combine IAC with direct tumor injections. This dual approach helps avoid enucleation even in complex cases where standard systemic chemotherapy has failed.

Patient Consensus: Parents prioritize finding neurointerventional expertise to manage delicate catheterization risks. Most feel relieved discovering this method can preserve their child’s vision and avoid surgical eye removal.

Intra-arterial chemotherapy (IAC) in Israel maintains high success rates within oncology centers reporting an average 90% positive outcome for cancer treatments. Specialty facilities like Sourasky Medical Center utilize IAC for targeted tumor delivery, combining precision medicine with JCI-accredited safety standards.

• Oncology success rate: Major centers like Sourasky report a 90% average for oncology treatments.
• Localized precision: IAC delivers high drug concentrations directly to tumors while sparing healthy tissue.
• Specialized expertise: Surgeons like Dr. Ronit El Hasid specialize in advanced intra-arterial delivery methods.
• Facility volume: Academic medical centers treat up to 40,000 cancer patients annually using the latest protocols.

Bookimed Expert Insight: Israeli medical centers often outperform global averages due to their rapid adoption of precision technologies. For example, some clinics offer specialized intra-arterial chemotherapy for pediatric and ocular cases that are rarely available elsewhere. While the procedure itself costs $2,400 to $5,500, the integration of genetic testing ensures the highest possible success for each patient.

Patient Consensus: Patients emphasize the importance of requesting specific clinical trial data for their cancer type. They recommend confirming if the chemotherapy package includes baseline genetic screening to improve outcome accuracy.

Intra-arterial chemotherapy (IAC) is superior for treating advanced retinoblastoma because it delivers highly concentrated medication directly into the ophthalmic artery. This targeted approach achieves 100% globe retention in group D cases, compared to 57% with intravenous methods, while significantly reducing systemic toxicity.

• Eye salvage rates: IAC reduces the need for eye removal from 56% to only 5%.
• Local drug density: High concentrations directly reach solid tumors, subretinal seeds, and vitreous seeds.
• Reduced side effects: Avoiding systemic delivery prevents common issues like anemia, immunosuppression, and nausea.
• Natural growth: Targeted delivery does not inhibit the natural growth of the child's eye.

Bookimed Expert Insight: While IAC excels in preserving vision for advanced unilateral cases, Israel’s top oncology centers like Sourasky Medical Center (Ichilov) utilize it as a critical second-line treatment. Dr. Ronit El Hasid’s team manages cases that originally failed systemic chemotherapy, successfully preventing enucleation in patients who previously had few options left.

Patient Consensus: Families often select IAC specifically to preserve vision in stage E cases. Parents report relief that this local approach avoids the long-term physical side effects typically seen with traditional full-body chemotherapy.

Intra-arterial chemotherapy (IAC) in Israel carries targeted risks including thromboembolism, ischemia, and localized tissue necrosis due to direct arterial injection. Specialist centers like Sourasky and Sheba mitigate these through real-time imaging, minimizing systemic side effects while focusing high-dose treatment on specialized tumors.

• Arterial complications: Risk of arterial injury, blood clots, or localized ischemia during catheterization procedures.
• Targeted toxicity: Possible tissue damage or necrosis if chemotherapy agents enter non-target arterial branches.
• Neurological safety: Potential for peripheral neuropathy or localized nerve irritation near the injection site.
• Systemic monitoring: Reduced but present risks of vein hardening or typical chemotherapy-related immune suppression.

Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center manage high-risk cases with a volume of 40,000 cancer patients annually. This massive throughput allows teams to master arterial access, which is critical since success depends on precise catheter placement. Clinics here often use advanced linear accelerators and genetic testing to complement IAC, ensuring the drug choice matches the tumor profile before high-concentration delivery begins.

Patient Consensus: Patients emphasize the need to clarify if IAC is for retinoblastoma or systemic tumors, as recovery expectations vary. Many note that monitoring for limb paleness or pain immediately after infusion is a vital practical step for safety.

Intraarterial chemotherapy in Israel is highly effective for patients who have not responded to standard systemic treatments. This localized approach delivers up to 600% higher drug concentrations directly to tumors while bypassing systemic toxicity. It frequently succeeds by targeting new pathways or shrinking lesions previously considered inoperable.

• Localized drug delivery: Targets tumors directly, bypassing resistance mechanisms developed during systemic chemotherapy sessions.
• Higher dosage: Delivers significantly higher drug concentrations while protecting healthy organs from severe toxicity.
• Combined strategies: Integrates systemic therapy with regional intraarterial methods for better tumor control.
• Advanced alternatives: Clinics like Sheba offer in-house CAR-T manufacturing for refractory or relapsed cancers.

Bookimed Expert Insight: Israeli oncology centers like Sourasky or Sheba excel by transitioning patients from palliative to curative paths. Data shows clinics here use intraarterial delivery specifically to shrink liver lesions until they become surgically removable. This aggressive strategy turned inoperable cases into successful surgeries for many of our patients.

Patient Consensus: Patients value the ability to receive aggressive treatment without the typical full-body side effects of chemotherapy. Many noted that monitoring liver health is intense but necessary to manage the high local drug doses effectively.

Intra-arterial chemotherapy (IAC) in Israel treats localized solid tumors including liver cancer, retinoblastoma, and pancreatic cancer. Leading JCI-accredited centers like Sourasky Medical Center and Sheba Medical Center utilize this targeted approach to deliver high-dose agents directly to the tumor via its feeding artery.

• Liver tumors: Used for primary liver cancer and metastases to maximize localized drug concentration.
• Retinoblastoma treatment: Often a primary therapy for child-specific unilateral eye cancers at Sourasky.
• Pancreatic cancer: Direct arterial infusion delivers potent chemotherapy while sparing surrounding healthy tissue.
• Brain malignancies: Applied in select cases to bypass the protective blood-brain barrier effectively.

Bookimed Expert Insight: Israeli oncology centers like Sourasky serve over 40,000 cancer patients annually, creating a massive data pool for precision medicine. While IAC is effective, clinics here frequently integrate it with Foundation One CDx genetic testing. This ensures the drugs delivered arterially are the most effective match for your tumor's specific DNA profile.

Patient Consensus: Patients emphasize confirming whether you need IAC or Israeli innovations like Alpha DaRT radiation needles. They recommend contacting oncology departments at Sheba or Ichilov directly to verify the latest protocol for your specific tumor location.

Intra-arterial chemotherapy in Israel is an interventional radiology procedure delivering concentrated medication directly to tumors via feeding arteries. This targeted approach minimizes systemic side effects while maximizing local drug efficacy. Specialists use microcatheters to treat advanced liver, brain, and ocular cancers in high-volume JCI-accredited centers.

• Catheter insertion: Surgeons insert a microcatheter through the femoral or radial artery.
• Image guidance: Real-time fluoroscopy ensures precise placement within the tumor-feeding vessels.
• Drug delivery: Chemotherapy is infused directly into the target area over 30–120 minutes.
• Hospital stay: Most patients remain for brief observation or 1 night in-hospital.

Bookimed Expert Insight: Israeli oncology centers like Sheba and Sourasky operate at massive scales, managing millions of patient visits annually. This high volume allows for ultra-specialized protocols, such as intra-arterial delivery for rare pediatric tumors. Accessing these advanced treatments often requires a private consultation to bypass standard waiting lists.

Patient Consensus: Patients emphasize verifying if the procedure is catheter-based infusion or isolated perfusion to set expectations. Marking referrals as urgent can often expedite the treatment start to within 2 weeks.